Moreover, oral DMF (30 mg/kg, daily) enhances the antitumor effect of sunitinib (20 mg/kg, every other day) in vivo in the 786-O cells xenograft model, supporting its potential as a novel therapeutic strategy for ccRCC through disruption of the HNF1B–YAP axis (Dai et al., 2025). The gene discussed is HNF1B; the disease is nonpapillary renal cell carcinoma.